A laxative composition and its preparation method and application

Abstract

The invention discloses a laxative composition and a preparation method and application thereof, and belongs to the technical field of veterinary medicine. The laxative composition of the invention comprises the following components: camellia seeds, tangerine peel, lotus flower, white ox gall, ox gall powder, propolis, liquorice and camellia oil. Animal experiments have shown that the laxative composition of the invention can significantly promote intestinal peristalsis and defecation of mice in a constipation model group, increase the levels of gastrin and vasoactive intestinal peptide in mouse serum and regulate intestinal microbial abundance, and the laxative composition can also significantly improve the constipation symptoms of sows. The laxative composition of the invention can effectively assist in lubricating the intestine and promoting defecation, has a significant therapeutic effect on constipation, is simple to prepare, has no toxic side effects, and has broad application prospects.

Description

Technical Field

[0001] The present invention relates to the technical field of veterinary drugs, and in particular to a laxative composition and a preparation method and application thereof. Background Art

[0002] Constipation is one of the most common digestive system diseases. It is common in elderly animals in veterinary clinics. Its symptoms include difficulty in defecation, low defecation frequency, incomplete defecation, and hardened feces. These symptoms persist for a long time, seriously affecting the production performance of livestock and poultry, and restricting the development of the breeding industry. In addition, sow constipation is also one of the more serious problems in animal husbandry production. The incidence of sow constipation increases with the increase of sow parity. The higher the parity, the higher the incidence of sow constipation. According to statistics, the average incidence of sow constipation is 33.4%, and the incidence of sow constipation in summer is as high as 60%. After constipation occurs, sows may experience prolonged labor or even dystocia. In severe cases, the body temperature rises, mastitis-metritis-galactia syndrome is induced, stillbirths occur, piglet diarrhea, and reduced milk production, which seriously affect the economic benefits of pig farms.

[0003] At present, the main treatments for constipation in veterinary clinics include adjusting feed structure, increasing exercise, reasonable drug treatment, biofeedback treatment, etc., but the above treatment methods are not effective in clinical practice and are prone to recurrence. Traditional Chinese medicine calls constipation "constipation", which is caused by heat in the large intestine, resulting in excessive drying of feces by the large intestine. Therefore, in terms of treatment principles, clearing heat and removing stagnation should be the main treatment. In addition, pregnant female animals should avoid using drugs with strong laxative effects, and should be used to moisten and relieve constipation. Therefore, this prescription is based on the treatment principles of clearing heat and removing stagnation, moistening and relieving constipation. Studies have shown that Chinese medicine can treat constipation by regulating intestinal flora and other methods. Existing research statistics have found that the current health foods and medicines for treating constipation that use Chinese medicine compositions as the main ingredients to assist in moistening the intestines and relieving constipation have many problems such as incomplete product information, duplication, lack of correlation between the medicinal properties and formulation rules of Chinese medicine formulas, and unstable efficacy. Therefore, it is urgent to explore a Chinese medicine laxative composition with stable efficacy and clear formulation rules for moistening the intestines and treating constipation, reducing the risk of concurrent diseases in patients with constipation, and improving the quality of life of patients with constipation. Summary of the invention

[0004] The purpose of the present invention is to provide a laxative composition and a preparation method and application thereof to solve the problems existing in the above-mentioned prior art. The composition provided by the present invention can significantly promote intestinal peristalsis, regulate intestinal microbial abundance, and improve constipation symptoms.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] The present invention provides a laxative composition, which comprises the following components by weight:.

[0007] 6-10 parts of camellia seeds, 2-5 parts of tangerine peel, 4-5 parts of lotus flowers, 1-2 parts of white ox gall, 1-3 parts of ox gall powder, 5-8 parts of propolis, 0.5-1.5 parts of licorice and 0.5-1.5 parts of camellia oil.

[0008] Preferably, the following components are included by weight:

[0009] 8 parts of camellia seeds, 4 parts of dried tangerine peels, 4 parts of flos rosaefoliae, 2 parts of white ox gallbladders, 1 part of ox gallbladder powder, 5 parts of propolis, 1 part of liquorice and 1 part of camellia oil.

[0010] The invention also provides application of the composition in preparing health-care food that helps to moisten the intestine and promote bowel movements.

[0011] The invention also provides a health-care food which helps to moisten the intestines and promote bowel movements, the main component of which is the composition.

[0012] Preferably, food-friendly excipients are also included.

[0013] The present invention provides the use of the composition in preparing a medicine for treating constipation

[0014] The invention also provides a medicine for treating constipation, the main component of which is the composition.

[0015] Preferably, a pharmaceutically acceptable excipient is also included.

[0016] Preferably, the dosage form of the drug includes decoction, powder, paste, pills and granules.

[0017] The present invention also provides a method for preparing the drug, comprising the following steps:

[0018] Weigh the corresponding mass of the drug raw material according to the formula of the composition;

[0019] Drying camellia seeds;

[0020] Mix camellia seeds, tangerine peel, lotus flower, white ox gall and liquorice, and grind into ultrafine powder;

[0021] The ultrafine powder is mixed with water, and subjected to condensation and reflux extraction to obtain an extract;

[0022] The extract is filtered under vacuum, the filtrate is collected, filtered again, the supernatant is separated, and concentrated into a paste to obtain an extract;

[0023] freeze-drying the extract to obtain dry powder;

[0024] Heat the block of propolis in water until it melts, take it out, and obtain the propolis;

[0025] Add ox bile powder, propolis and camellia oil to the dry powder, stir evenly, and obtain the product.

[0026] The present invention discloses the following technical effects:

[0027] The laxative composition of the present invention comprises 8 kinds of traditional Chinese medicines. Animal experiments show that the laxative composition can significantly promote intestinal peristalsis and defecation of mice in the constipation model group, increase the levels of gastrin and vasoactive intestinal peptide in mouse serum and regulate the abundance of intestinal microorganisms, and can also significantly improve the constipation symptoms of sows. The laxative composition of the present invention can effectively assist in moistening the intestines and relieving constipation, has a significant therapeutic effect on constipation, is simple to prepare, has no toxic side effects, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0029] Figure 1 This is the result of the ink propulsion experiment on the small intestine of mice;

[0030] Figure 2 The figure is a statistical chart of ink propulsion rate in the small intestine of mice; compared with the constipation model group, *P<0.05;

[0031] Figure 3 The first defecation time of mice is shown in the statistical chart; compared with the constipation model group, *P<0.05;

[0032] Figure 4 The figure is a statistical chart of the number of mouse feces; compared with the constipation model group, *P<0.05;

[0033] Figure 5 The figure is a statistical chart of mouse feces weight; compared with the constipation model group, *P<0.05;

[0034] Figure 6 The statistical diagram of fecal water content in mice; compared with the constipation model group, *P<0.05;

[0035] Figure 7 The statistical diagram of vasoactive intestinal peptide content in mice; compared with the constipation model group, *P<0.05;

[0036] Figure 8 The figure is a statistical diagram of gastrin content in mice; compared with the constipation model group, *P<0.05;

[0037] Fig. 9This is the sequencing result of mouse intestinal microbial richness; percentage is the percentage;

[0038] Fig.10 This is a statistical chart of sow constipation rate. DETAILED DESCRIPTION

[0039] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0040] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0041] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0042] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0043] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0044] Example 1 Preparation of laxative

[0045] 1. Drug formulation

[0046] Recipe 1: It comprises, by weight: 8 parts of camellia seeds, 4 parts of tangerine peel, 4 parts of lotus flowers, 2 parts of white ox gall, 1 part of ox gall powder, 5 parts of propolis, 1 part of licorice and 1 part of camellia oil.

[0047] Recipe 2: It includes, by weight: 10 parts of camellia seeds, 2 parts of tangerine peel, 5 parts of lotus flowers, 1 part of white ox gall, 2 parts of ox gall powder, 8 parts of propolis, 0.5 parts of licorice and 0.5 parts of camellia oil.

[0048] Recipe 3: It includes, by weight: 6 parts of camellia seeds, 5 parts of tangerine peel, 3 parts of lotus flowers, 1.5 parts of white ox gall, 3 parts of ox gall powder, 6 parts of propolis, 1.5 parts of licorice and 1.5 parts of camellia oil.

[0049] 2. Preparation method

[0050] According to the above formula, weigh the corresponding weight of the drug raw materials.

[0051] Dry camellia seeds at 105°C to constant weight; mix camellia seeds, tangerine peel, lotus flower, white ox gall and liquorice, and crush them into ultrafine powder by a wall-breaking machine; add 10 times the volume of water to the ultrafine powder, condense and reflux for extraction for 40 minutes to obtain an extract; vacuum negative pressure filter, collect the filtrate, filter and take the supernatant, concentrate it into a paste to obtain an extract; freeze-dry the extract to obtain a dry powder; heat the hard block of propolis to 50°C in water, take it out after it melts, and obtain propolis; add ox gall powder, propolis and camellia oil to the dry powder, stir evenly, granulate it with a granulator, dry it, and seal it for storage.

[0052] According to the drug ratios of Recipe 1, Recipe 2 and Recipe 3, three kinds of laxative granules were prepared by the above-mentioned preparation method, and the following experiments were carried out to verify the efficacy of the laxative granules.

[0053] Example 2 Mouse constipation experiment

[0054] 1. Mouse culture, grouping and modeling

[0055] 60 healthy female ICR mice, weighing 18±2g, all experimental animals were kept at 22-26℃, relative humidity varied between 40%-70%, all mice were kept in SPF cages, the day and night cycle was 12h light and 12h dark (8:00 to 20:00 every day). Each experimental animal was allowed to feed standard mouse food and water ad libitum, and during the experiment, feed, water and sterilized bedding were changed every night.

[0056] After one week of adaptive feeding, the mice were randomly divided into the following five groups: blank group, constipation model group, prescription 1 group, prescription 2 group, and prescription 3 group. The constipation model group, prescription 1 group, prescription 2 group, and prescription 3 group were gavaged with 5 mg / (g / d) loperamide hydrochloride every morning for 5 consecutive days to establish the constipation model.

[0057] After the model was established, the subjects in group 1, group 2, and group 3 were treated with the laxative composition prepared according to group 1, group 2, and group 3 in Example 1 for 3 consecutive days (1 g / kg body weight dose).

[0058] 2. Detection of constipation in mice

[0059] 2.1 Small bowel propulsion test

[0060] After the last administration, mice in each group were fasted for 12 h (without water restriction), and 3 mice were selected from each group. 30 min after loperamide hydrochloride administration, mice in the blank group, constipation model group, prescription group 1, prescription group 2, and prescription group 3 were given arabic gum ink (0.25 mL). Immediately after 30 min of intragastric administration of ink, the mice were killed by dislocation of the neck, the abdominal cavity was opened to separate the mesentery, the intestinal tube from the pylorus at the upper end and the ileocecal part at the lower end was cut, and placed on a tray, the small intestine was gently pulled into a straight line, the length of the small intestine was measured as the "total length of the small intestine", and the length from the pylorus to the front edge of the ink was measured as the "ink advancement length", and the ink advancement rate was calculated according to the following formula.

[0061] Ink propulsion rate = (ink propulsion length / total length of small intestine) × 100%.

[0062] The experimental results are as follows Figure 1 and Figure 2 As shown, compared with the blank group, the ink propulsion rate of mice in the constipation model group was significantly decreased (P<0.05), and compared with the constipation model group, the ink propulsion rate of mice in the prescription 1 group, prescription 2 group and prescription 3 group was significantly increased (P<0.05).

[0063] 2.2 Time of first defecation and stool particles within 6 hours

[0064] After the last administration, mice in each group were fasted for 12 hours (water was not allowed), and 3 mice were selected from each group. 30 minutes after loperamide hydrochloride was administered, the mice in the blank group, constipation model group, prescription 1 group, prescription 2 group, and prescription 3 group were given arabic gum ink (0.25 mL), and the timing was started at the same time. Each mouse was raised individually, and free water and food were available during the period. The time required for each mouse to excrete black stool for the first time and the number and weight of stool particles within 6 hours were observed and recorded. After the experiment, fresh feces were taken to determine its water content.

[0065] The experimental results are as follows Figure 3-Figure 6 As shown, compared with the blank group, the time to the first defecation of mice in the constipation model group was significantly increased, and the amount, weight and water content of feces were significantly decreased (P<0.05); compared with the constipation model group, the time to the first defecation of mice in the prescription 1 group, prescription 2 group and prescription 3 group was significantly decreased, and the amount, weight and water content of feces were significantly increased (P<0.05).

[0066] 2.3 Serum hormone level determination

[0067] After the treatment on the third day, six mice were killed (without fasting), and their blood was collected for serum separation, and their colon feces were collected for later use.

[0068] According to the instructions of Ruixin Bio's gastrin ELISA test kit (RX202573M) and vasoactive intestinal peptide ELISA test kit (RX202527M), the levels of gastrin and vasoactive intestinal peptide in mouse serum were detected, respectively.

[0069] The experimental results are as follows Figure 7 and Figure 8 As shown, compared with the blank group, the levels of gastrin and vasoactive intestinal peptide in the serum of mice in the constipation model group were significantly decreased (P<0.05); compared with the constipation model group, the levels of gastrin and vasoactive intestinal peptide in the serum of mice in the prescription 1 group, prescription 2 group and prescription 3 group were significantly increased (P<0.05).

[0070] 2.416s microbial richness sequencing

[0071] The mouse colon feces collected in 2.3 were used for 16S microbial richness sequencing. The sequencing results are as follows: Fig. 9 shown.

[0072] 2.4.1 Probiotics richness

[0073] Unclassified, uncultured and UCG-006 subgroups of Lactobacillus and Lachnospiraceae are important intestinal probiotics that participate in the metabolism of multiple carbohydrates, produce prebiotic factors such as volatile fatty acids such as acetate and butyrate, promote gastric acid secretion, digestion and gastrointestinal motility, effectively regulate the homeostasis of intestinal flora, and improve constipation symptoms.

[0074] 16S microbial sequencing analysis showed that the abundance of Lactobacillus in the feces of mice in the blank group was 40%, the abundance of Lactobacillus in the feces of mice in the constipation model group was 18%, and the abundance of Lactobacillus in the feces of mice in the prescription 1 group, prescription 2 group, and prescription 3 group were 33%, 30%, and 50%, respectively. This shows that laxative granules can significantly increase the abundance of lactic acid bacteria in the feces of mice in the constipation model group, increase the content of volatile fatty acids in the intestine, and thus improve constipation symptoms.

[0075] 16S microbial sequencing analysis also showed that compared with the blank group, the abundance of unclassified, uncultured and UCG-006 subgroups of Lachnospiraceae was significantly decreased. Compared with the constipation model group, the abundance of unclassified and uncultured subgroups of Lachnospiraceae in the feces of mice in Prescription 1, Prescription 2 and Prescription 3 groups was significantly increased, indicating that laxative granules can effectively increase the abundance of Lachnospiraceae in the feces of mice in the constipation model group, increase the content of volatile fatty acids in the intestine, and thus improve constipation symptoms.

[0076] 2.4.2 Richness of pathogenic bacteria

[0077] Bacteroidales is one of the conditional pathogens in the intestine. Under certain conditions, it can cause constipation, obesity, diabetes, enteritis, anorexia, abdominal distension, ADHD, chronic kidney disease, osteoporosis and many other diseases.

[0078] 16S microbial sequencing analysis showed that compared with the blank group, the richness of the Bacteroidetes S24-7_group_norank subgroup and the genus Bacteroides in the feces of mice in the constipation model group was significantly increased, while the richness of the Bacteroidetes S24-7_group_norank subgroup and the genus Bacteroides in the feces of mice in the prescription 1 group, prescription 2 group and prescription 3 group was significantly decreased, indicating that the laxative granules can effectively reduce the abundance of Bacteroidetes bacteria in the feces of mice in the constipation model group, thereby improving the symptoms of constipation.

[0079] Example 3 Sow constipation experiment

[0080] Sixty sows with severe constipation symptoms were evenly divided into four groups, with 15 in each group, namely control group, prescription group 1, prescription group 2 and prescription group 3; the control group was fed only basic feed, while prescription group 1, prescription group 2 and prescription group 3 were added with laxative granules of prescription 1, prescription 2 and prescription 3 at a mass ratio of 1% in the basic feed, respectively. The sows were fed continuously for 3 days, and the constipation conditions of the sows were recorded.

[0081] The experimental results are as follows Fig.10 As shown, compared with the control group, the constipation rates in Prescription 1, Prescription 2 and Prescription 3 groups were significantly decreased (P<0.05), indicating that laxative granules can effectively treat constipation in pigs.

[0082] The embodiments described above are only descriptions of the preferred embodiments of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A laxative composition for animals, characterized in that: By weight, it is composed of the following components: 6-10 parts of camellia seeds, 2-5 parts of tangerine peel, 4-5 parts of lotus flowers, 1-2 parts of white ox gall, 1-3 parts of ox gall powder, 5-8 parts of propolis, 0.5-1.5 parts of licorice and 0.5-1.5 parts of camellia oil.

2. The composition according to claim 1, characterized in that By weight, it is composed of the following components: 8 parts of camellia seeds, 4 parts of dried tangerine peels, 4 parts of flos rosaefoliae, 2 parts of white ox gallbladders, 1 part of ox gallbladder powder, 5 parts of propolis, 1 part of liquorice and 1 part of camellia oil.

3. Use of the composition according to any one of claims 1 to 2 in the preparation of an animal health feed that helps to moisturize the intestines and promote bowel movements.

4. An animal health feed that helps to moisten the intestines and promote bowel movements, characterized in that: The active ingredient is the composition according to any one of claims 1 to 2.

5. The animal health feed according to claim 4, characterized in that: Further feed-acceptable auxiliary materials are added.

6. Use of the composition according to any one of claims 1 to 2 in the preparation of veterinary drugs for treating constipation.

7. A veterinary drug for treating constipation, characterized in that: The active ingredient is the composition according to any one of claims 1 to 2.

8. The veterinary drug according to claim 7, characterized in that: Pharmaceutically acceptable excipients are further added.

9. The veterinary drug according to claim 7, characterized in that: The dosage forms of the veterinary medicine include decoction, powder, paste, pills and granules.

10. The method for preparing the veterinary drug according to any one of claims 7 to 9, characterized in that: The following steps are involved: Weigh corresponding mass of drug raw materials according to the composition; Drying camellia seeds; Mix camellia seeds, tangerine peel, lotus flower, white ox gall and liquorice, and grind into ultrafine powder; The ultrafine powder is mixed with water, and subjected to condensation and reflux extraction to obtain an extract; The extract is filtered under vacuum, the filtrate is collected, filtered again, the supernatant is separated, and concentrated into a paste to obtain an extract; freeze-drying the extract to obtain dry powder; Heat the block of propolis in water until it melts, take it out, and obtain the propolis; Add ox bile powder, propolis and camellia oil to the dry powder, stir evenly, and obtain the product.

Images